[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349791-105":59,"doc-detail-349791-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","major-clinical-advances-in-gynecologic-cancer-in-2025-from-de-escalation-strategies-to-precision-therapies-beyond-brca-review-article","Major clinical advances in gynecologic cancer in 2025 - from de-escalation strategies to precision therapies beyond BRCA - review article","","The landscape of gynecologic cancer management has evolved substantially in 2025, with advances spanning surgical, radiation, and systemic therapies. Precision oncology has expanded treatment options beyond the BRCA era, incorporating immune checkpoint inhibitors for selected molecular and histopathologic profiles. Biomarker-driven approaches and antibody-drug conjugates are refining and improving efficacy across multiple disease settings. Combination strategies are increasingly emphasized, alongside surgical and radiation advances focused on functional preservation and quality of life without compromising oncologic outcomes. This review highlights notable 2025 research and future implications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/major-clinical-advances-in-gynecologic-cancer-in-2025-from-de-escalation-strategies-to-precision-therapies-beyond-brca-review-article/349791/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/major-clinical-advances-in-gynecologic-cancer-in-2025-from-de-escalation-strategies-to-precision-therapies-beyond-brca-review-article/349791.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major treatment domains advanced in gynecologic cancer during 2025?","Question",{"text":112,"@type":113},"Advances span surgical, radiation, and systemic therapies, with emphasis on maintaining oncologic outcomes while improving function and quality of life.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How has precision oncology changed options beyond the BRCA era?",{"text":117,"@type":113},"Precision approaches broaden therapeutic choices and support strategies guided by distinct molecular and histopathologic features, extending treatment considerations beyond BRCA-focused paradigms.",{"name":119,"@type":110,"acceptedAnswer":120},"What new therapeutic class is described as promising in multiple disease settings?",{"text":121,"@type":113},"Antibody–drug conjugates are highlighted as a promising class, combining tumor-targeted antibodies with cytotoxic payloads and showing encouraging antitumor activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349791,1792811339,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","J Gynecol Oncol. 2026 Jan;37(1):e62 [https://doi.org/10.3802/jgo.2026.37.e62](https://doi.org/10.3802/jgo.2026.37.e62)[ ](https://doi.org/10.3802/jgo.2026.37.e62)pISSN 2005-0380·eISSN 2005-0399  \nReview Article  \nReceived: Jan 9, 2026  \nRevised: Jan 10, 2026  \nAccepted: Jan 11, 2026  \nPublished online: Jan 16, 2026  \nCorrespondence to  \nDong Hoon Suh  \nDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea.  \nEmail: [sdhwcj@naver.com](sdhwcj@naver.com)  \n*Sung Jong Lee and Ji Geun Yoo contributed equally to this work.  \n© 2026. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nSung Jong Lee  [https://orcid.org/0000-0002-6077-2649](https://orcid.org/0000-0002-6077-2649)[ ](https://orcid.org/0000-0002-6077-2649)Ji Geun Yoo  [https://orcid.org/0000-0001-5359-8729](https://orcid.org/0000-0001-5359-8729)[ ](https://orcid.org/0000-0001-5359-8729)Jin Hwi Kim  [https://orcid.org/0000-0002-1591-1611](https://orcid.org/0000-0002-1591-1611)[ ](https://orcid.org/0000-0002-1591-1611)Mais Mohammed IAlhulwah  [https://orcid.org/0000-0002-5003-8301](https://orcid.org/0000-0002-5003-8301)[ ](https://orcid.org/0000-0002-5003-8301)EmadAli Y Jabrah  [https://orcid.org/0009-0007-1032-8519](https://orcid.org/0009-0007-1032-8519)[ ](https://orcid.org/0009-0007-1032-8519)[Jeong-Yeol Park](Jeong-Yeol Park)  [https://orcid.org/0000-0003-2475-7123](https://orcid.org/0000-0003-2475-7123)  \nMajor clinical advances in gynecologic cancer in 2025: from de-escalation strategies to precision therapies beyond BRCA  \nSung Jong Lee ,1,* Ji Geun Yoo ,2,* Jin Hwi Kim ,3  \nMais Mohammed I Alhulwah ,1 Emad Ali Y Jabrah ,1 Jeong-Yeol Park ,4 Jung-Yun Lee ,5 Yoo-Young Lee ,6 Dong Hoon Suh  7  \n1Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n2Department of Obstetrics and Gynecology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea  \n3Department of Obstetrics and Gynecology, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea  \n4Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea  \n5Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea 6Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  \n7Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea  \nABSTRACT  \nThe landscape of gynecologic cancer management has continued to evolve substantially in 2025, driven by major clinical advances spanning surgical, radiation, and systemic therapies. Recent progress in precision oncology has expanded therapeutic options beyond the BRCA era. Immune checkpoint inhibitors have become integral components of treatment for selected gynecologic malignancies characterized by distinct molecular and histopathologic features, while novel biomarker-driven approaches continue to refine patientselection. In addition, antibody–drug conjugates, which combine tumor-targeted antibodies with cytotoxic payloads, have emerged as a promising therapeutic class, demonstrating encouraging antitumor activity across multiple disease settings. In an effort to overcome the limitations of novel single-agent therapies, clinical research has increasingly focused on combinatio","cbCaiarlJecM1uOh","https://ap.wps.com/l/cbCaiarlJecM1uOh","pdf",1373554,15,"English","# Introduction\n## Treatment evolution in 2025\n## Precision oncology beyond BRCA\n## Immunotherapy and biomarker-driven approaches\n## Antibody-drug conjugates\n## Combination strategies and multimodal advances\n## Surgical and radiation technique priorities\n# Conflict of Interest and Author Contributions","[{\"question\":\"What major treatment domains advanced in gynecologic cancer during 2025?\",\"answer\":\"Advances span surgical, radiation, and systemic therapies, with emphasis on maintaining oncologic outcomes while improving function and quality of life.\"},{\"question\":\"How has precision oncology changed options beyond the BRCA era?\",\"answer\":\"Precision approaches broaden therapeutic choices and support strategies guided by distinct molecular and histopathologic features, extending treatment considerations beyond BRCA-focused paradigms.\"},{\"question\":\"What new therapeutic class is described as promising in multiple disease settings?\",\"answer\":\"Antibody–drug conjugates are highlighted as a promising class, combining tumor-targeted antibodies with cytotoxic payloads and showing encouraging antitumor activity.\"}]","Major clinical advances in gynecologic cancer in 2025 - from de-escalation strategies to precision therapies beyond BRCA - review article | PDF",1790085592,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a680b4a89a0a239f3a50d831a6b696f3.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37f28da934f2e8dbc8ec65671d8d2968.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/639ef9d2b2cc9993fdd23e06f2b92d14.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b740c28b5dc2f16c232896a4ff26b2a3.webp",980,1306]